We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A triumph for physiology driving drug discovery: the potential impact of dipeptidyl peptidase-IV inhibitors in type 2 diabetes.
- Authors
Donnelly, Richard
- Abstract
The author reflects on the drug discovery of dipeptidyl peptidase-IV inhibitors and its potential impact in the physiology of type 2 diabetic patients. It mentions the results of several multicentre, randomized controlled trials with vildagliptin and sitagliptin. An overview of the drugs approved by United States Food and Drug Administration for diabetes patients is offered including sitagliptin.
- Subjects
CD26 antigen; TYPE 2 diabetes; PHARMACODYNAMICS; UNITED States. Food &; Drug Administration
- Publication
Diabetes, Obesity & Metabolism, 2007, Vol 9, Issue 2, p151
- ISSN
1462-8902
- Publication type
Editorial
- DOI
10.1111/j.1463-1326.2007.00706.x